A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

771

Enrollment

INDUSTRY

Sponsor class

Conditions

Facial Papulopustular Rosacea

Interventions

DRUG: FMX103 minocycline foam 1.5%
DRUG: Vehicle foam

Sponsor

Vyne Therapeutics Inc.

Collaborators

[object Object]